A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006

Inclusion Criteria:

- Age ≥ 18 years

- Subjects are receiving ongoing treatment with AGS-003 in protocol AGS- 003-004
or AGS-003-006.

- Measurable disease that can be monitored per RECIST throughout the course of study
participation.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Adequate hematologic function, as defined by the following criteria:

1. White blood cell (WBC) ≥ 4000/µL (≥ 4.0 x 103/µL)

2. Absolute neutrophil count (ANC) ≥ 1500/µL (≥ 1.5 x 103/µL)

3. Platelets ≥ 100,000/µL (≥ 100 x 103/µL)

4. Hemoglobin (Hgb) ≥ 9.0 g/dL

- Adequate renal and hepatic function, as defined by the following criteria:

1. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or, if serum creatinine >
1.5 x ULN, estimated glomerular filtration rate (eGFR) ≥ 30 mL/min

2. Total serum bilirubin ≤ 1.5 x ULN

3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤
2.5 x ULN, or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to
underlying malignancy

- Adequate coagulation function as defined by the following criteria:

1. Prothrombin time (PT) ≤ 1.5 x ULN

2. Activated partial thromboplastin time (PTT) < 1.5 x ULN

3. Corrected calcium ≤ 11.5 mg/dL

- Negative serum pregnancy test for female subjects with reproductive potential, and
agreement of all male and female subjects of reproductive potential to use a reliable
form of contraception during the study and for 12 weeks after the last dose of study
drug

- Able to abstain from taking prohibited drugs, either prescription or non-
prescription, during the treatment phase of the study

- Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests, and other study procedures

- Signed and dated informed consent document indicating that the subject (or legally
acceptable representative) has been informed of all pertinent aspects of the trial
prior to enrollment

- No brain metastases detected by magnetic resonance imaging (MRI).

Exclusion Criteria:

- Any serious medical condition considered by the investigator to constitute an
unwarranted high risk for investigational treatment

- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis, or evidence of brain or leptomeningeal disease on screening computed
tomography (CT) scan or MRI

- Pregnancy or breastfeeding

- Active autoimmune disease or condition requiring chronic immunosuppressive therapy

NOTE: Abnormal laboratory values for autoimmunity markers in the absence of other
signs/symptoms of autoimmune disease are not exclusionary.